Monogram Orthopaedics (MGRM) Stock Price, News & Analysis

Company Overview

Monogram Orthopaedics, Inc. (NASDAQ: MGRM) is a medical device company focused on the design, manufacture and commercialization of patient-specific implants and instrumentation for corrective osteotomy procedures. Leveraging advanced 3D imaging and additive manufacturing technologies, the company aims to improve surgical precision and patient outcomes in the treatment of knee osteoarthritis and related deformities. By tailoring implants and surgical guides to individual anatomy, Monogram seeks to reduce intra-operative variability and accelerate post-operative recovery.

The company’s core offerings include personalized angular stable plates and cutting guides for high tibial osteotomy (HTO), distal femoral osteotomy (DFO) and tibial tubercle osteotomy (TTO). Each implant and instrument is planned using proprietary software that converts CT or MRI scans into a detailed surgical blueprint, allowing surgeons to execute pre-planned corrections with high accuracy. Monogram’s additively manufactured implants feature optimized geometry and variable stiffness zones designed to support natural bone healing under load.

Founded in 2014 and headquartered in Santa Clara, California, Monogram Orthopaedics has established commercial operations across the United States and Europe. The company has obtained FDA clearance for its osteotomy system in the U.S. and secured CE marking for its products in the European Union. Monogram collaborates closely with leading orthopedic centers and imaging facilities to streamline patient workflow and expand clinical adoption of its technology platform.

Under the leadership of Chief Executive Officer Nathan Engler, a veteran of the orthopedic industry, Monogram continues to invest in research and development aimed at broadening its anatomical applications and enhancing its digital planning tools. As the company scales its manufacturing capabilities and builds strategic partnerships, it seeks to address unmet needs in deformity correction and to set new standards in personalized orthopedic care.

Key Stats

• Today's Range: $5.64 to $5.75
• 50-Day Range: $2.41 to $5.91
• 52-Week Range: $1.92 to $6.02
• Volume: 199,776 shs
• Average Volume: 316,609 shs
• Market Capitalization: $204.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $5.40
• Consensus Rating: Strong Buy

Monogram Orthopaedics Stock Analysis - MarketRank™

Monogram Orthopaedics scored higher than 16% of companies evaluated by MarketBeat, and ranked 828th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Monogram Orthopaedics has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Monogram Orthopaedics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Monogram Orthopaedics are expected to grow in the coming year, from ($0.49) to ($0.46) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Monogram Orthopaedics is -12.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Monogram Orthopaedics is -12.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Monogram Orthopaedics has a P/B Ratio of 13.64. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.14% of the float of Monogram Orthopaedics has been sold short.

Short Interest Ratio / Days to Cover

Monogram Orthopaedics has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Monogram Orthopaedics has recently increased by 6.36%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Monogram Orthopaedics does not currently pay a dividend.

Dividend Growth

Monogram Orthopaedics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.14% of the float of Monogram Orthopaedics has been sold short.

Short Interest Ratio / Days to Cover

Monogram Orthopaedics has a short interest ratio ("days to cover") of 8.1.

Change versus previous month

Short interest in Monogram Orthopaedics has recently increased by 6.36%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Monogram Orthopaedics this week, compared to 1 article on an average week.

Search Interest

2 people have searched for MGRM on MarketBeat in the last 30 days.

MarketBeat Follows

Only 2 people have added Monogram Orthopaedics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Monogram Orthopaedics insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.10% of the stock of Monogram Orthopaedics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.45% of the stock of Monogram Orthopaedics is held by institutions.

MGRM Stock Analysis - Frequently Asked Questions

How have MGRM shares performed this year?

Monogram Orthopaedics' stock was trading at $2.37 at the beginning of the year. Since then, MGRM shares have increased by 141.8% and is now trading at $5.73.

How were Monogram Orthopaedics' earnings last quarter?

Monogram Orthopaedics Inc. (NASDAQ:MGRM) issued its quarterly earnings data on Wednesday, May, 14th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02.
Read the conference call transcript.

When did Monogram Orthopaedics IPO?

Monogram Orthopaedics (MGRM) raised $17 million in an IPO on Thursday, May 18th 2023. The company issued 2,374,641 shares at $7.25 per share.

How do I buy shares of Monogram Orthopaedics?

Shares of MGRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Monogram Orthopaedics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Monogram Orthopaedics investors own include Mullen Automotive (MULN), Faraday Future Intelligent Electric (FFIE), Plug Power (PLUG), AMC Entertainment (AMC), CXApp (CXAI), Draganfly (DPRO) and

Company Calendar

• Last Earnings: 5/14/2025
• Today: 7/22/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:MGRM
• CIK: 1769759
• Web: www.monogramorthopedics.com
• Phone: 512-399-2656
• Fax: N/A
• Employees: 28
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Monogram Orthopaedics: $5.40
• High Price Target: $5.40
• Low Price Target: $5.40
• Potential Upside/Downside: -5.8%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.45)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$16.33 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -115.71%
• Return on Assets: -92.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.00
• Quick Ratio: 7.00

Sales & Book Value

• Annual Sales: $370 thousand
• Price / Sales: 552.71
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.42 per share
• Price / Book: 13.64

Miscellaneous

• Outstanding Shares: 35,690,000
• Free Float: 25,660,000
• Market Cap: $204.50 million
• Optionable: Not Optionable
• Beta: 0.59